Instrument Inactif

Autres langues Ocata Therapeutics Inc

Actions

US67457L1008

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

Autres langues

10/02/16	Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
22/01/16	Ocata Therapeutics : Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
28/12/15	Ocata Therapeutics : Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells
03/12/15	Ocata Therapeutics : Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis
11/11/15	OCATA THERAPEUTICS : Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.
10/11/15	Ocata Therapeutics : Brower Piven Commences An Investigation Into The Proposed Sale Of Ocata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information
10/11/15	Ocata Therapeutics : Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Astellas Pharma Inc.
10/11/15	Ocata Therapeutics : Astellas to Acquire Ocata Therapeutics
06/11/15	Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Third Quarter of 2015
23/09/15	Ocata Therapeutics : to Present at Ladenburg Thalmann 2015 Healthcare Conference
22/09/15	Ocata Therapeutics : Canine Patients Treated with Ocata’s Hemangio-derived Mesenchymal Cells (HMC™) Achieve Remission in a Model of Crohn’s Disease
08/09/15	Ocata Therapeutics : First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD
03/09/15	Ocata Therapeutics : Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer
01/09/15	Ocata Therapeutics : Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa
31/08/15	Ocata Therapeutics : Appoints Dr. Brian Levy to its Board of Directors
24/08/15	Ocata Therapeutics : Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis
19/08/15	Ocata Therapeutics : Secures $10 Million in Debt Financing
06/08/15	Ocata Therapeutics : Provides Corporate Update for the Second Quarter of 2015
31/07/15	Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015
15/07/15	Ocata Therapeutics : Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
14/07/15	Ocata Therapeutics : Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus
01/07/15	Ocata Therapeutics : to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
30/06/15	Ocata Therapeutics : Added to Russell 2000, 3000, Global and Microcap Indices
24/06/15	Ocata Therapeutics : Announces Positive Results Reported in a Late Breaking Abstract at the Annual Meeting of the International Society for Stem Cell Research
18/06/15	Ocata Therapeutics : to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015